Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
 

This article is part of the supplement: Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts .

Open AccessOral presentation

Mouse APOBEC3 affects the production of virus-neutralizing antibodies by restricting early retroviral replication, not by altering the B-cell repertoire

Masaaki Miyazawa, Sachiyo Tsuji-Kawahara, Tomomi Chikaishi, Maiko Kato and Shiki Takamura

Department of Immunology, Kinki University School of Medicine, Osaka-Sayama, Osaka, Japan 589-8511

corresponding author email

from Frontiers of Retrovirology: Complex retroviruses, retroelements and their hosts
Montpellier, France. 21-23 September 2009

Retrovirology 2009, 6(Suppl 2):O9doi:10.1186/1742-4690-6-S2-O9

The electronic version of this abstract is the complete one and can be found online at: http://www.retrovirology.com/content/6/S2/O9

Published: 24 September 2009

© 2009 Miyazawa et al; licensee BioMed Central Ltd.

Oral presentation

Recent genetic analyses have indicated that polymorphisms in the mouse APOBEC3 locus constitute the Rfv3 gene that influences the production of virus-neutralizing antibodies in mice infected with Friend leukemia retrovirus [1,2]. Mice of the resistant genotype preferentially express the exon 5-lacking transcript in higher levels, while susceptible mice express the full-length transcript in lower levels [2,3]. Mouse APOBEC3 expressed in the resistant strains restricts the replication of mouse retroviruses in vitro through a mechanism independent of its deaminase activity [2]. However, the mechanisms through which mouse APOBEC3 affects the production of virus-neutralizing antibodies remain unclear. To address this question, we analyzed retroviral replication and the production of virus-neutralizing antibodies in mice of different APOBEC3 genotypes and those lacking its expression.

Strain A mice with the susceptible APOBEC3 genotype nevertheless produced high levels of virus-neutralizing antibodies when they possessed the H-2b haplotype, and class-switching to IgG was observed in the presence of virus-specific T helper cells. Further, APOBEC3-deficient mice produced virus-neutralizing antibodies when their T helper cells had been primed with the viral antigen. Friend virus-induced derangements in the hematopoiesis and resultant splenomegaly are not directly responsible for the delayed antibody responses, because higher levels of viremia and lower antibody responses were observed upon infection with nonpathogenic Friend murine leukemia helper virus in the absence of APOBEC3. In mice of the resistance-associated APOBEC3 genotype lower levels of viremia were observed even before the detection of virus-neutalizing antibodies in the blood, indicating that the polymorphisms in the APOBEC3 locus affect the production of neutralizing antibodies as a result of restricted retroviral replication.

Conclusion

B cells from the mice of susceptible APOBEC3 genotypes produce neutralizing antibodies in the presence of virus-specific T helper cells. Polymorphisms in the APOBEC3 affect the levels of viremia prior to the production of neutralizing antibodies, indicating that APOBEC3 may indirectly influence B cell functions by restricting viral replication.

References

  1. Santiago ML, Montano M, Benitez R, Messer RJ, Yonemoto W, Chesebro B, Hasenkrug KJ, Greene WC: Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.

    Science 2008 , 321:1343-1346. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  2. Takeda E, Tsuji-Kawahara S, Sakamoto M, Langlois MA, Neuberger MS, Rada C, Miyazawa M: Mouse APOBEC3 restricts Friend leukemia virus infection and pathogenesis in vivo.

    J Virol 2008 , 82:10998-11008. PubMed Abstract | Publisher Full Text | PubMed Central Full Text OpenURL

  3. Okeoma CM, Petersen J, Ross SR: Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection.

    J Virol 2009 , 83:3029-3038. PubMed Abstract | Publisher Full Text OpenURL

Have something to say? Post a comment on this article!


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.